# V1 Empirics Check — mistralai/mistral-large-2512 (Variant C)

**Model:** mistralai/mistral-large-2512
**Variant:** C
**Date:** 2026-03-13T16:31:19.056681

---

### **Idea Fidelity**
The paper closely follows the original manifest. It uses the staggered DiD design with Sun and Abraham’s (2021) estimator, leverages CMS Hospital Compare data (OP-18b, OP-22), and tests the PE-owned staffing firm mechanism via ownership heterogeneity. The falsification test using self-insured plans (ERISA-exempt) is mentioned but not implemented, which is a missed opportunity. The paper also omits the physician staffing substitution test (FTE physicians vs. NPs/PAs) and the welfare analysis proposed in the manifest. These omissions weaken the mechanistic interpretation but do not undermine the core identification.

---

### **Summary**
This paper provides the first causal evidence on whether state surprise billing laws degraded emergency department (ED) quality of care. Using staggered adoption across nine states (2015–2018) and CMS Hospital Compare data on ED wait times and left-without-being-seen (LWBS) rates, the authors implement a robust DiD design (Sun and Abraham 2021) and find a well-powered null: no detectable effect on ED quality. The confidence intervals rule out economically meaningful effects, while ownership heterogeneity suggests (but does not confirm) a private equity-driven mechanism.

---

### **Essential Points**
1. **Plausibility of Magnitudes and Standard Errors**
   - The null effects are plausible given the partial treatment intensity (ERISA preemption limits state laws to ~40% of commercially insured patients). However, the standard errors (SE = 0.74 for ED time, SE = 0.077 for LWBS) may be *too small* given the limited number of treated states (9) and the high within-state correlation of ED outcomes. The authors cluster at the state level (50 clusters), but the effective number of independent treated units is closer to 4 (cohorts) or 9 (states). A wild bootstrap or randomization inference would provide more conservative inference.
   - The event-study coefficients at *k* = −4 and *k* = −5 are concerning. The authors dismiss these as compositional artifacts, but they could reflect differential pre-trends in ED crowding (e.g., urbanization, hospital closures) that are unrelated to surprise billing laws. A placebo test using a non-ED outcome (e.g., inpatient mortality) would help rule out this confound.

2. **Mechanism Tests Are Inconclusive**
   - The ownership heterogeneity results (for-profit hospitals: +1.60 minutes, SE = 1.01) are suggestive of a PE-driven mechanism but are not statistically significant. The authors should explicitly test whether PE-owned hospitals (using data from Cooper et al. 2024 or LaPointe 2023) respond differently to the laws. Without this, the paper’s claim to contribute to the PE-healthcare literature is overstated.
   - The significant placebo (OP-20, door-to-diagnostic time) is troubling. The authors argue this is not a true placebo because triage speed could respond to staffing changes, but this is unconvincing. A better placebo would be an inpatient quality measure (e.g., 30-day readmissions) that is unaffected by ED staffing but captures underlying hospital trends.

3. **Economic Meaningfulness of the Null**
   - The paper frames the null as "reassuring," but the economic interpretation is ambiguous. The null could reflect:
     - (a) No meaningful revenue shock (due to ERISA preemption or substitution to other billing channels).
     - (b) Revenue shocks that were absorbed through non-quality margins (e.g., physician pay cuts).
     - (c) Quality degradation on unmeasured margins (e.g., diagnostic accuracy, patient satisfaction).
   - The authors should explicitly discuss these alternatives and acknowledge that the null does not rule out quality degradation on unmeasured dimensions.

---

### **Suggestions**
#### **1. Strengthen Inference**
   - **Re-estimate standard errors using a wild bootstrap or randomization inference.** Given the small number of treated states, state-clustered SEs may understate true uncertainty. A wild bootstrap (Cameron et al. 2008) or permutation test would provide more conservative inference.
   - **Test for pre-trends using a non-ED outcome.** Use inpatient mortality or readmissions as a placebo to rule out differential trends in hospital quality unrelated to surprise billing laws. If these outcomes show pre-trends, the parallel trends assumption is violated.

#### **2. Sharpen Mechanism Tests**
   - **Directly test PE ownership heterogeneity.** Merge hospital-year data on PE-owned ED staffing (from Cooper et al. 2024 or LaPointe 2023) and interact with the treatment. This would provide a cleaner test of the PE mechanism than ownership type.
   - **Implement the ERISA falsification test.** Hospitals treating mostly self-insured (ERISA-exempt) patients should show no response to state laws. This is a critical test of the identification strategy and should be included in the main results.
   - **Test physician staffing substitution.** Use CMS cost reports to examine whether hospitals reduced physician FTEs or increased NP/PA FTEs after the laws. This would provide direct evidence of cost-cutting.

#### **3. Improve Interpretation of the Null**
   - **Clarify the economic interpretation of the null.** The null could reflect attenuation due to ERISA preemption, substitution to other revenue channels, or quality degradation on unmeasured margins. The authors should explicitly discuss these alternatives and avoid framing the null as "no harm" without caveats.
   - **Acknowledge the limitations of the quality measures.** OP-18b (wait times) and OP-22 (LWBS) are process measures that may not capture clinical quality (e.g., diagnostic accuracy, patient satisfaction). The authors should discuss whether the laws could have affected unmeasured quality dimensions.
   - **Discuss the generalizability to the No Surprises Act.** The federal No Surprises Act (2022) has broader scope (no ERISA preemption) and may produce larger effects. The authors should explicitly note that their results may not generalize to the federal law.

#### **4. Address the Placebo Outcome**
   - **Replace OP-20 with a true placebo.** Use an inpatient quality measure (e.g., 30-day readmissions) that is unaffected by ED staffing but captures underlying hospital trends. If this placebo shows no pre-trends, it would strengthen the parallel trends assumption.
   - **Alternatively, drop the placebo test.** The current placebo (OP-20) is not convincing and raises more questions than it answers. The authors should either replace it or omit it.

#### **5. Minor Improvements**
   - **Clarify the treatment intensity.** The authors note that state laws apply to ~40% of commercially insured patients, but they should quantify the expected revenue shock. For example, if out-of-network billing accounted for 20% of ED revenue, the law would reduce revenue by ~8% (20% × 40%). This would help readers assess the plausibility of the null.
   - **Report standardized effect sizes in the main text.** The standardized effect sizes (0.008 SD for ED time, 0.037 SD for LWBS) are buried in the appendix. These should be reported in the abstract and main results to help readers assess the economic significance.
   - **Discuss the power of the study.** The authors should report the minimum detectable effect (MDE) for their sample size and design. This would help readers assess whether the study was adequately powered to detect meaningful effects.
   - **Clarify the event-study composition.** The authors should explicitly note which cohorts contribute to each event-study coefficient (e.g., *k* = −5 is driven by New York and Connecticut). This would help readers interpret the pre-trends and post-treatment estimates.

#### **6. Broaden the Discussion**
   - **Discuss the implications for the No Surprises Act.** The federal law has broader scope and may produce larger effects. The authors should discuss whether their results generalize to the federal law and what additional evidence is needed.
   - **Discuss the welfare implications.** The manifest proposed a welfare analysis (consumer surplus from reduced OOP minus welfare loss from increased wait times). The authors should at least discuss how their results inform this trade-off, even if they cannot implement the full analysis.
   - **Engage with the broader literature on provider payment regulation.** The authors cite Clemens and Gottlieb (2014) and Ho and Pakes (2014), but they should explicitly discuss how their results fit into this literature. For example, do their results suggest that provider payment regulation has limited effects on quality, or is this a special case due to the partial treatment intensity?

---

### **Conclusion**
This is a well-executed paper with a clear research question and robust identification strategy. The null results are plausible and economically meaningful, but the authors must address the concerns about standard errors, pre-trends, and mechanism tests. With the suggested improvements, this paper could make a strong contribution to the literature on surprise billing, private equity in healthcare, and provider payment regulation.
